Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $21.74 Analyst target: $56.00 Upside: 157.59%
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops and sells candidates for orally administered small molecule drugs to meet unmet medical needs.
See the full interactive analysis & chart →Informational only — not investment advice.